This was not a significant differene from the combination alone, suggesting that IL-4 and CD40L signaling can only partially overcome the increased cell death caused by the combination treatment, depending on the CLL patient. The gene discussed is CD40LG; the disease is B-cell chronic lymphocytic leukemia.